Company: HCWB
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0000950170-25-046724
Chunk: 14

Company: HCW Biologics Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1
Chunk 14
---
 in indications that are being studied in clinical trials. 

•We intend to work with the strongest principal investigators who have a passion for the underlying science and search for breakthrough therapeutics.  These investigators tend to have gravitas at their institutions and the broader scientific and medical communities.  We find they can often be advocates for HCW Biologics and our clinical studies.

Balance clinical development of our proprietary molecules between a few in-house development programs and licensing programs with larger biotech companies and big pharma for other molecules.    

•For in-house development, we will focus on HCW9302 and second-generation immune checkpoint inhibitors.  After the completion of Phase 1 studies in China, the Company may also elect to exercise our Opt-In Right per the WY Biotech License Agreement, and add HCW11-006 to our in-house development programs for the Americas market. 

•We plan to begin actively seeking a partner for the development of the Company’s T-Cell Engager and other Immune Cell Engagers in Q2 2025.  

•We will continually assess candidates for clinical development for licensing.  The Company has created over 50 compounds using the TRBC platform which it owns, many of which show bioactivity and potential for development for the treatment of diseases linked to inflammation and aging, such as cancer.

13 

Our Programs

The Company created two novel drug discovery platforms, using two distinctly different scaffolds to anchor the composition of immunotherapeutic fusions.  This results in the creation of molecules with different mechanisms of action, which opens up different pathways for treatment of diseases promoted by chronic inflammation.  

Our Proprietary T-Cell Receptor β Chain Constant Region Drug Discovery and Development Platform

HCW Biologics invented the TRBC drug discovery and development platform, a second-generation drug discovery technology platform, to create immunotherapeutics that activate immune responses and specifically target cancerous or infected cells. The platform utilizes the TRBC protein as a scaffold to build multi-chain chimeric polypeptides, which include target-binding domains and affinity domains, enabling the targeting of specific antigens. We believe these polypeptides stimulate immune cells, modulating immune functions and signaling pathways. 

Molecules created with the TRBC platform integrate multiple protein targets, such as cytokines, single-chain antibodies, and ligands, into a single fusion complex designed to engage immunostimulatory functions and modulate various signaling pathways. This flexible, adaptable platform has facilitated the development of a groundbreaking pipeline of internally developed product candidates.